Conditions: Melanoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 31
Healthy volunteers: no

Brief summary:
The purpose of the study is to determine whether additional doses of ipilimumab have a positive effect on survival in the treatment of advanced melanoma that has progressed after successful initial treatment with ipilimumab.

Detailed description:

Arms:
arm 1: Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent arm 2: Participants received the investigator's choice of chemotherapy, administered per package instructions.

Interventions: intervention 1: Ipilimumab intervention 2: Chemotherapy
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: